Immunotherapies

News Immunotherapies

• Novel coronavirus well-adapted to humans, susceptible to immunotherapy

  The new coronavirus that has emerged in the Middle East is well-adapted to infecting humans but could potentially be treated with immunotherapy, according to a study to be published online in the journal of the American Society for Microbiology. The study indicates that the virus HCoV-EMC can penetr more

• Immunity drives cancer into permanent growth arrest
  

  Martin Röcken and his team at the Department of Dermatology, Eberhard Karls University Tuebingen, found that anti-cancer immunity is capable of driving cancers and single cancer cells into a permanent growth arrest. Scientifically this permanent growth arrest is called senescence. As complete cancer more

• Novartis and University of Pennsylvania form broad-based R&D alliance to advance novel T-cell immunotherapies to treat cancer

  Novartis and the University of Pennsylvania (Penn) announced an exclusive global collaboration to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers. In addition, the parties will jointly establish a new research and development more

Publications Immunotherapies

• Molecular programming of steady‐state dendritic cells: impact on autoimmunity and tumor immune surveillance

  Dendritic cells are master regulators of immunity. Immature dendritic cells are essential for maintaining self‐tolerance, while mature dendritic cells initiate a variety of specialized immune responses. Dendritic cell quiescence is often viewed as a default state that requires exogenous stimuli to more

• A comparison of immunotherapy delivery methods for allergen immunotherapy

  Background: Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged. Methods: Selective literature research in Medline and Pu more

• Sizing up a slow assault on cancer

  Sizing up a slow assault on cancer Nature 496, 7443 (2013). http://www.nature.com/doifinder/10.1038/496014a Author: Heidi Ledford Rise of immunotherapies spurs search for markers of response. more

Market studies Immunotherapies

• Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global melanoma therapeutics market. The report identifies the key more

• R&D Trends: Prostate Cancer - Newly approved therapies shift treatment dynamics for castrate-resistant disease

  Introduction The late-phase prostate cancer pipeline is dominated by targeted therapies, closely followed by immunotherapies. There are a growing number of therapies with novel targets such as Zibotentan (AstraZeneca) which targets endothelin-A (ET-A). Identification of the correct molecular target more

• Entest BioMedical Inc. (ENTB) - Financial and Strategic SWOT Analysis Review

  Entest BioMedical Inc. (Entest), a majority owned subsidiary of Bio-Matrix Scientific Group Inc. The company is engaged in the development of stem cell therapy for the treatments of chronic obstructive pulmonary disease (COPD), testing procedures, cancer immuno-therapies and stem cell research appli more

Websites Immunotherapies